RxDoctor Payments Data

Ashraf Andrawis, MD

Pain Medicine · Orange Park, FLNPI 1568445666

Payments from drug & device makers

$6,962in general payments, 2019–2025

Across 435 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Collegium Pharmaceutical, Inc.$913
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$691
  • Merz North America, Inc.$336
  • Amgen$317
  • Biohaven Pharmaceuticals, Inc.$230
  • plus $2K from 41 others

What the payments were for

  • Food & beverage$6,928100%
  • Education$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,962 in reported general payments places this provider in the 70th percentile of 596 pain medicine providers in Florida.

See all pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$412,810
Medicare patients
609
Services billed
7,934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate374$172,893
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen4,603$138,684
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen5,277$121,050
MovantikNaloxegol Oxalate152$63,321
UbrelvyUbrogepant24$58,461
BelbucaBuprenorphine Hcl56$46,421
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl315$44,068
Gabapentin2,591$30,126
Pregabalin1,587$27,522
ZubsolvBuprenorphine Hcl/Naloxone Hcl31$27,163
Morphine Sulfate ErMorphine Sulfate1,062$24,791
SuboxoneBuprenorphine Hcl/Naloxone Hcl35$24,354
BotoxOnabotulinumtoxina15$19,595
Fentanyl168$15,636
Tizanidine Hcl1,894$13,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$913$219,314430 claims
AbbVieUbrelvy, Botox, Linzess$2,314$90,32862 claims
Redhill Biopharma Inc.Movantik$25$63,321152 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine, Morphine Sulfate, Buprenorphine Hcl$19$51,674473 claims
Orexo US, Inc.Zubsolv$101$27,16331 claims
Indivior Inc.Suboxone$131$24,35435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 596 pain medicine providers in Florida.

Other pain medicine in Orange Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →